Patents by Inventor James E. Darnell, Jr.

James E. Darnell, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7417120
    Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1? was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40-50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat1 known to be phosphorylated in vivo.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: August 26, 2008
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, James E. Darnell, Jr.
  • Patent number: 7368293
    Abstract: HNF-4 (hepatocyte nuclear factor 4) is a protein enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 protein (54 kD) and isolated a cDNA clone encoding the protein. HNF-4 is a member of the steroid hormone receptor superfamily with an unusual amino acid in the conserved “knuckle” of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine as well as liver but is absent in other tissues.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: May 6, 2008
    Assignee: The Rockefeller University
    Inventors: Frances M. Sladek, Weimin Zhong, James E. Darnell, Jr.
  • Patent number: 7339039
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted With interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN? and IFN?. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: March 4, 2008
    Assignee: The Rockfeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 7211655
    Abstract: The present invention relates to methods for identifying interacting regions of transcription factors, and methods for identifying agents which modulate the interactions, useful for affecting gene regulation, for example, cellular transformation. A site within residues 130–154 and within residues 343–358 in Stat3 were found to interact with the transcription factor c-Jun. On c-Jun, a site within residues 105 and 334, and more particularly, between 105 and 263, interact with Stat3. These sites of interactions permit methods for identifying agents which modulate the interaction between these transcription factors to modulate gene transcription.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: May 1, 2007
    Assignee: The Rockefeller University
    Inventors: Xiaokui Zhang, Curt Horvath, Melissa H. Wrzeszczynska, James E. Darnell, Jr.
  • Patent number: 7115567
    Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1? was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40–50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat1 known to be phosphorylated in vivo.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: October 3, 2006
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, James E. Darnell, Jr.
  • Patent number: 7060682
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN? and IFN?. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: June 13, 2006
    Assignee: The Rockefeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 6960647
    Abstract: The present invention relates to methods for identifying interacting regions of transcription factors, and methods for identifying agents which modulate the interactions, useful for affecting gene regulation, for example, cellular transformation. A site within residues 130-154 and within residues 343-358 in Stat3 were found to interact with the transcription factor c-Jun. On c-Jun, a site within residues 105 and 334, and more particularly, between 105 and 263, interact with Stat3. These sites of interactions permit methods for identifying agents which modulate the interaction between these transcription factors to modulate gene transcription.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: November 1, 2005
    Assignee: The Rockefeller University
    Inventors: Xiaokui Zhang, Curt Horvath, Melissa H. Wrzeszczynska, James E. Darnell, Jr.
  • Patent number: 6720154
    Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1&agr; was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40-50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat 1 known to be phosphorylated in vivo.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: April 13, 2004
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, James E. Darnell, Jr.
  • Patent number: 6605442
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN&agr; and IFN&ggr;. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: August 12, 2003
    Assignee: The Rockefeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 6500672
    Abstract: HNF-4 (hepatocyte nuclear factor 4) is a protein enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 protein (54 kD) and isolated a cDNA clone encoding the protein. HNF-4 is a member of the steroid hormone receptor superfamily with an unusual amino acid in the conserved “knuckle” of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine as well as liver but is absent in other tissues.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: December 31, 2002
    Assignee: The Rockefeller University
    Inventors: Frances M. Sladek, Weimin Zhong, James E. Darnell, Jr.
  • Patent number: 6391572
    Abstract: The present invention relates to methods for identifying interacting regions of transcription factors, and methods for identifying agents which modulate the interactions, useful for affecting gene regulation, for example, cellular transformation. A site within residues 130-154 and within residues 343-358 in Stat3 were found to interact with the transcription factor c-Jun. On c-Jun, a site within residues 105 and 334, and more particularly, between 105 and 263, interact with Stat3. These sites of interactions permit methods for identifying agents which modulate the interaction between these transcription factors to modulate gene transcription.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: May 21, 2002
    Assignee: The Rockefeller University
    Inventors: Xiaokui Zhang, Curt Horvath, Melissa H. Wrzeszczynska, James E. Darnell, Jr.
  • Patent number: 6338949
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN&agr; and IFN&ggr;. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: January 15, 2002
    Assignee: The Rockefeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 6312887
    Abstract: The present invention provides a crystal containing the N-terminal domain of a STAT protein that is of sufficient quality to perform X-ray crystallographic studies. Methods of preparing the crystals are include in the invention. The present invention further discloses the three-dimensional structure of the crystal. The present invention also provides methods of using the structural information in drug discovery and drug development.
    Type: Grant
    Filed: April 24, 2000
    Date of Patent: November 6, 2001
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, Ismail Moarefi, James E. Darnell, Jr., John Kuriyan
  • Patent number: 6235873
    Abstract: The invention is directed to constitutively active Stat proteins and methods for their preparation. The modified Stat proteins have at least one cysteine residue which may interact with the corresponding cysteine residue on another modified Stat protein to form a dimer. The constitutively active Stat proteins are capable of binding to DNA and activating transcription in the absence of tyrosine phosphorylation. Cell lines expressing the modified Stat protein exhibit a transformed phenotype and are capable of forming tumors in nude mice. Methods are describe utilizing the modified Stat proteins of the invention in the absence and presence of tyrosine phosphorylation in identifying agents capable of modulating Stat protein dimerization, transcriptional activity, and cellular transformation in vitro and in vivo. The invention is also directed to polynucleotides encoding modified, constitutively active Stat proteins.
    Type: Grant
    Filed: July 31, 1999
    Date of Patent: May 22, 2001
    Assignee: The Rockefeller University
    Inventors: Jacqueline F. Bromberg, Melissa H. Wrzeszczynska, Yanxiang Zhao, James E. Darnell, Jr.
  • Patent number: 6160092
    Abstract: The present invention provides a crystal of the core portion of the STAT protein in dimeric form with an 18-mer duplex DNA that contains a binding site for the STAT-dimer. The crystal is of sufficient quality to perform X-ray crystallographic studies. Methods of preparing the crystals are include in the invention. The present invention further discloses the three-dimensional structure of the crystal. The present invention also provides methods of using the structural information in drug discovery and drug development.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: December 12, 2000
    Assignee: The Rockefeller University
    Inventors: Xiaomin Chen, Uwe Vinkemeier, Yanxiang Zhao, David Jeruzalmi, James E. Darnell, Jr., John Kuriyan
  • Patent number: 6124118
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN.alpha. and IFN.gamma..
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: September 26, 2000
    Assignee: The Rockfeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 6087478
    Abstract: The present invention provides a crystal containing the N-terminal domain of a STAT protein that is of sufficient quality to perform X-ray crystallographic studies. Methods of preparing the crystals are include in the invention. The present invention further discloses the three-dimensional structure of the crystal. The present invention also provides methods of using the structural information in drug discovery and drug development.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: July 11, 2000
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, Ismail Moarefi, James E. Darnell, Jr., John Kuriyan
  • Patent number: 6030780
    Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1.alpha. was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40-50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat1 known to be phosphorylated in vivo.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: February 29, 2000
    Assignee: The Rockefeller University
    Inventors: Uwe Vinkemeier, James E. Darnell, Jr.
  • Patent number: 6030808
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN.alpha. and IFN-.gamma..
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: February 29, 2000
    Assignee: The Rockefeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 6025196
    Abstract: HNF-4 (hepatocyte nuclear factor 4) is a protein enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 protein (54 kD) and isolated a cDNA clone encoding the protein. HNF-4 is a member of the steroid hormone receptor superfamily with an unusual amino acid in the conserved "knuckle" of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine as well as liver but is absent in other tissues.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: February 15, 2000
    Assignee: The Rockefeller University
    Inventors: Frances M. Sladek, Weimin Zhong, James E. Darnell, Jr.